Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Completes Fermentas Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its $260 million acquisition of Fermentas International.

Fermentas sells reagents for nucleic acid and protein purification, restriction and modifying enzymes, molecular weight markers, and other life science research and diagnostic tools. It also offers various products for polymerase chain reaction, reverse transcription PCR, and quantitative PCR.

The firm will be integrated into Thermo Fisher's Analytical Technologies segment.

Based in Burlington, Ontario, with principal operations in Vilnius, Lithuania, Fermentas employs about 500. In 2009, it posted revenues of about C$57 million ($54 million).

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.